PLSE 8-K: SEC filing
Pulse Biosciences
Filed with the SEC on · accession 0001437749-26-035265
PLSE filed a 8-K (current report) with the SEC on Nov 5, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Pulse Biosciences reported Q3 2026 financial results and business updates, highlighted by completion of enrollment in the NANOPULSE-AF US IDE pivotal study three months ahead of plan and a strengthened balance sheet with $189.2 million in cash after raising $95.8 million via ATM programs.
Key details
✦ Ask GOAX AI about this filing — what it means for PLSE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PLSE?
Click hereFrequently asked questions
What did PLSE file with the SEC on Nov 5, 2026?
PLSE filed a 8-K (SEC filing). Pulse Biosciences reported Q3 2026 financial results and business updates, highlighted by completion of enrollment in the NANOPULSE-AF US IDE pivotal study three months ahead of plan and a strengthened balance sheet with $189.2 million in cash after raising $95.8 million via ATM programs.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other PLSE SEC filings
- 8-K · Contract winOct 14, 2026
- 8-K · Fda approvalOct 7, 2026
- 8-K · Fda approvalSep 15, 2026
- 424B5 · Secondary offeringSep 15, 2026
- 8-K · Secondary offeringSep 15, 2026
- 424B5 · Secondary offeringAug 6, 2026
- 8-K · Guidance raiseAug 6, 2026
- 10-Q · SEC filingAug 6, 2026
- 8-K · Secondary offeringAug 6, 2026
- 8-K · Fda approvalJul 29, 2026
Get alerts when PLSE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days